CA2418070C - Hybrid neuroprosthesis for the treatment of brain disorders - Google Patents
Hybrid neuroprosthesis for the treatment of brain disorders Download PDFInfo
- Publication number
- CA2418070C CA2418070C CA2418070A CA2418070A CA2418070C CA 2418070 C CA2418070 C CA 2418070C CA 2418070 A CA2418070 A CA 2418070A CA 2418070 A CA2418070 A CA 2418070A CA 2418070 C CA2418070 C CA 2418070C
- Authority
- CA
- Canada
- Prior art keywords
- drug
- brain
- subject
- microcontroller
- subcutaneously
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000014644 Brain disease Diseases 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 121
- 229940079593 drug Drugs 0.000 claims abstract description 121
- 210000004556 brain Anatomy 0.000 claims abstract description 67
- 238000012377 drug delivery Methods 0.000 claims abstract description 43
- 230000000694 effects Effects 0.000 claims abstract description 16
- 230000001722 neurochemical effect Effects 0.000 claims abstract description 12
- 229920002529 medical grade silicone Polymers 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 30
- 210000002569 neuron Anatomy 0.000 claims description 11
- 238000004891 communication Methods 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 210000004289 cerebral ventricle Anatomy 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000010304 firing Methods 0.000 claims description 5
- 238000007914 intraventricular administration Methods 0.000 claims description 5
- 238000001690 micro-dialysis Methods 0.000 claims description 5
- 229920001971 elastomer Polymers 0.000 claims description 4
- 239000000806 elastomer Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 2
- 244000287680 Garcinia dulcis Species 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 230000009977 dual effect Effects 0.000 abstract description 2
- 230000035992 intercellular communication Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 26
- 241000700159 Rattus Species 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000002397 epileptogenic effect Effects 0.000 description 6
- 210000001320 hippocampus Anatomy 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 241001631457 Cannula Species 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 229960003965 antiepileptics Drugs 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 2
- 229910005813 NiMH Inorganic materials 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001787 epileptiform Effects 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 230000002109 interictal effect Effects 0.000 description 2
- 238000000185 intracerebroventricular administration Methods 0.000 description 2
- 229910001416 lithium ion Inorganic materials 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000005442 molecular electronic Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 239000002071 nanotube Substances 0.000 description 2
- 230000008062 neuronal firing Effects 0.000 description 2
- 230000003957 neurotransmitter release Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000002637 putamen Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000005641 tunneling Effects 0.000 description 2
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000010476 Respiratory Paralysis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 210000003105 phrenic nerve Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- -1 second messengers Proteins 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
- A61N1/0531—Brain cortex electrodes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/903—Specified use of nanostructure for conversion, containment, or destruction of hazardous material
Abstract
A miniature apparatus for the treatment of brain disorders is provided which is a combination of electronic and pharmacological devices placed and powered entirely within the human body. The apparatus is based on the dual, electrical-molecular, nature of intercellular communication in the brain. The hybrid neuroprosthesis monitors the electrical activity of a dysfunctioning brain area, analyzes the incoming electrical signals, and delivers drug molecules into the dysfunctioning area to correct its function. The apparatus delivers drugs into the brain in such a way that the timing and duration of the drug deliveries are determined by the brain's own electrical activity. The hybrid neuroprosthesis includes: (a) an electrophysiological recording electrode implanted in a dysfunctioning brain site; (b) a miniature electrical signal conditioner to amplify, filter and digitize the incoming electrophysiological signals; (c) a cannula or catheter implanted in the dysfunctioning brain site;
(d) a miniature, refillable pump for driving drug solutions through the cannula or catheter; (e) a microcontroller which analyzes on-line the digitized electrophysiological signals and either activates or inactivates the pump on the basis of the analyzed electrophysiological data; (f) a miniature radiotelemetry system which provides data transfer between the apparatus and the outside world; and (g) a rechargeable power supply to power the components of the apparatus. The recording electrode can be complemented with a neurochemical sensor to transmit not only electrophysiological but also neurochemical information from the dysfunctioning brain area to the microcontroller. The components of the apparatus are encapsulated in medical grade silicon.
(d) a miniature, refillable pump for driving drug solutions through the cannula or catheter; (e) a microcontroller which analyzes on-line the digitized electrophysiological signals and either activates or inactivates the pump on the basis of the analyzed electrophysiological data; (f) a miniature radiotelemetry system which provides data transfer between the apparatus and the outside world; and (g) a rechargeable power supply to power the components of the apparatus. The recording electrode can be complemented with a neurochemical sensor to transmit not only electrophysiological but also neurochemical information from the dysfunctioning brain area to the microcontroller. The components of the apparatus are encapsulated in medical grade silicon.
Description
HYERID NEUROPROSTHESIS FOR THE
TREATMENT OF BRAIN DISORDERS
The present invention relates generally to the treatment of brain disorders, and more particularly, to a hybrid neuropr0sthesis apparatus implanted subcutaneously in a human subject.
At the dawn of the year 2000, effective therapy is still unavailable for the treatment of Alzheimer's disease and other degenerative disorders, stroke is still the third leading cause of death in the United States after heart disease and cancer, and currently marketed drugs are still ineffective in about 60% of patients with complex partial seizures. These few examples may demonstrate that the challenges for neurology and psychiatry in the new century will be as enormous as the achievements of these medical fields in the past one. New therapeutic strategies are needed, which capitalize on the progress in drug research, molecular biology, computer technology and electronics. Constructing neuroprosthetic devices is part of these efforts.
The first generation of successful neuroprosthesis included diaphragm pacing devices to stimulate the phrenic nerve in patients with respiratory paralysis, the Neurocybernetic Prosthesis for seizure control via vagus nerve stimulation, and 2o cochlear implants for acoustic name stimulation in individuals with hearing loss. A
second generation of neuroprostheses, designed to restore sensory and motor functions are under development in various laboratories. A common feature of these existing and experimental neuroprosthetic devices is that they stimulate the neural tissue electrically.
However, the neurons of the brain are not merely living electronic machines. While these cells indeed transmit information to other neurons with the use of purely electrical tools referred to as "action potentials", the generation and spacing of action potentials are regulated by molecular mechanisms. In fact, these mechanisms are sophisticated interplays of a large number of infra- and extracellular molecular systems. Thus, the neurons work as molecular-electronic computers, as they process their inputs with molecular mechanisms in order to generate electrical outputs.
The hybrid neuroprosthesis device of the present invention is essentially the translation of the dual: molecular-electronic nature of neurons into a medical device. The term "hybrid neuroprosthesis" refers to a subcutaneously implanted miniature apparatus which simultaneously acts as an electrophysiological data recorder and a drug delivery means such as a pump. This allow it to monitor the electrical activity of a dysfunctioning brain area and to correct the dysfunction by delivering drugs into the environment of the abnormal neurons.
Accordingly, the hybrid neuroprosthesis of the present invention fundamentally differs from all prior neuroprostheses, as the hybrid neuroprosthesis aims to correct neural dysfunctions pharmacologically, and not electrically.
The advantage of the hybrid neuroprosthesis approach is that with drugs neuron-and synapse-specific actions can be achieved, which is difficult to accomplish with electrical stimulations.
The hybrid neuroprosthesis of the present invention also differs from the intracerebral drug delivery technologies of the prior art. No prior intracerebral drug delivery systems, including drug-loaded ethylene vinyl acetate copolymer (EVAc) rods, are able to monitor the electrical activity of the targeted brain tissue. As a consequence, no feed-back is obtained from the targeted tissue. This may lead to too high, therefore damaging, or too low, therefore ineffective, drug concentrations.
No prior intracerebral drug delivery systems can apply the drug solutions periodically, only when this intervention is necessary.
Indeed, a device is needed which is able to monitor the electrical activity of a dysfunctioning brain area without interfering with the patient's daily Life, yet also being able to deliver drugs into the dysfunctioning brain area:
precisely when it is necessary. The hybrid neuroprosthesis device of the present invention satisfies this need, especially since the device can also be extended to monitoring not only the electrical but also the neurochemical activity of the dysfunctioning brain area and to deliver drugs into this area in response to either the neurochemical signals, or the electrical signals, or both.
The present invention provides an apparatus and methods for the treatment of brain disorders which overcomes the problems of the prior art.
The present invention also provides an apparatus and methods for the treatment of brain disorders which stimulates brain tissue by pharmacological stimulation.
Further, the present invention provides an apparatus and methods for the treatment of brain disorders which can be used in controlled human studies.
Still further, the present invention provides an apparatus and methods for the treatment of brain disorders for analyzing neuronal firing in natural circumstances, during behavior.
Still even further, the present invention provides an apparatus and methods for the treatment of brain disorders in which a delivered eh-ug solution does not affect the cells of the whole body which can drastically change the subject's behavior.
to In addition, the present invention provides an apparatus and methods for the treatment of brain disorders which regulates intracerebral drug delivery.
Accordingly, an apparatus for the treatment of brain disorders in a subject is provided. The apparatus comprises: a drug delivery means implanted in the subject for delivering at least one drug solution to the brain of the subject;
a drug 15 driving means that drives the at least one dmg solution to the drug delivery means; a recording electrode implanted in the brain for outputting an electrical signal characteristic of an electrical activity of the brain; and a microcontroller for controlling the drug driving means on the basis of the electrical signal.
Preferably, the entire apparatus is subcutaneously disposed in the subject. Preferably, the recording 20 electrode is complemented with a sensor to detect neurochemical signals such as neurotransmitter release or other molecular events. Alternatively, the recording electrode is replaced by a neurochemical sensor.
The drug delivery means is preferably a cannula, such as a mufti-port cannula having a plurality of ports, each port delivering the drug solution to a corresponding portion of the brain or an intraventricular cannula for delivering the drug solution to a substantial portion of the brain. Alternatively, the drug delivery means can be a catheter, microdialysis probe, or other drug ejector device.
The drug delivery means is implanted in the brain of the subject or in the ventricular system of the subj ect.
The drug driving means is preferably a pump, that includes a drug reservoir for holding the at least one drug solution and which is also preferably subcutaneously disposed in the subject and is externally accessible on the surface of the skin for periodic refilling. Alternatively, the drug driving device can be a microcapillary device, nanotube, microtube, microfabricated pathway using electrokinetic force, or other components.
The apparatus preferably further comprises an electrical signal conditioner disposed between the recording electrode and the microcontroller for amplifying, filtering and digitizing the recorded electrical signals from the brain and inputting the conditioned signals to the microcontroller, wherein the electrical signal conditioner is also preferably subcutaneously disposed in the subject.
The microcontroller is preferably equipped with a microprocessor, to 2o analyze the electrophysiological data stream from the electrical signal conditioner and regulate the drug driving means accordingly. Alternatively, the microcontroller can be a digital signal processor (DSP), a programmable logical array (PLA), a programmable logical device (PLD), an application-specific integrated circuit (ASIC), or other similar device. The processor can be equipped with a transmitter to transmit, preferably via a communication system, the analyzed electrophysiological signals to outside of the body for more advanced human and computer analysis. The processor is preferably further equipped with a receiver to receive, preferably via a communication system, human and computer commands from outside of the body.
The apparatus still further comprises a power source, such as a battery, for supplying power to the drug driving device, the microcontroller and the electrical signal conditioner. The battery is preferably a NiMH or Lithium-ion battery which is l0 also subcutaneously disposed in the subject and is rechargeable from the outside of the body from an electromagnetic or optical power source. Alternatively, the power source is a subcutaneous current generator.
In a preferred configuration of the apparatus, the microcontroller, the drug driving means, the electrical signal conditioner and the battery are housed in a 15 single container subcutaneously disposed in the subject. The container is preferably an elastomer case fabricated from medical grade silicon and is subcutaneously disposed in the subject at the base of the brain and back of the neck.
Alternatively, the microcontroller, the drug driving means, the electrical signal conditioner and the power source can be housed in individual containers, located in distant body parts 2o under the skin, and are interconnected via subcutaneous tunneling.
Also provided are methods for the treatment of brain disorders with the apparatus of the present invention.
These and other features, aspects, and advantages of the apparatus and methods of the present invention will become better understood with regard to the following description, appended claims, and accompanying drawings where:
Figure 1A illustrates the hybrid neuroprosthesis of the present invention subcutaneously disposed in a subject.
Figure 1B illustrates an enlarged view of the hybrid neuroprosthesis of Fig. 1 A.
Figure 1C illustrates an alternative configuration of the hybrid neuroprosthesis of the present invention.
to Figure 2 illustrates the schematic diagram of a preferred implementation of the electrical signal conditioner - microcontroller unit of Figure 1B.
Figure 3 illustrates an alternative version of the hybrid neuroprosthesis of Fig. 1 B.
15 Figures 4A and 4B illustrate normal and abnormal neuronal firing patterns in the rat hippocampus, respectively.
Figure 5 presents an experimental model for the hybrid neuroprosthesis concept, showing EEG recordings from the epileptogenic hippocampus of a rat before and after the microinjection of an antiepileptic drug solution directly into the 20 dysfunctioning hippocampal area.
Although this invention is applicable to numerous and various types of subjects, it is particularly useful in the environment of human subjects.
Therefore, without limiting the applicability of the invention to human subjects, the apparatus and methods of the present invention will be described in such an environment.
The term "hybrid neuroprosthesis" as used herein refers to a microprocessor-controlled, intracerebrally implanted drug delivery device, in which the timing and duration of the drug deliveixes are determined by the implanted brain tissue's own electrical activity. Thus, the device is a "hybrid" of pharmacological and electrophysiological instruments. The pharmacological components are: (1) a drug delivery device such as a cannula, catheter, or microdialysis probe chronically implanted in the ventricular system or in the brain tissue, and (2) a miniature, l0 subcutaneously placed drug reservoir/drug driving means, which can be periodically refilled. The electrophysiological components are: (1) a recording electrode chronically implanted in the brain, and (2) a miniature, subcutaneously placed electrical signal conditioner. A processor, alternatively referred to as a microcontroller, placed in close proximity to these components, both analyzes the 15 electrophysiological data and controls the drug reservoir/drug driving means. All of these components are powered by a nearby power supply, such as a battery, and sealed in a biocompatible case.
Referring now to Figures 1A, 1B, and 1C in combination, there is illustrated an apparatus for the treatment of brain disorders in a subject, the apparatus 2o being generally referred to by reference numeral 100, the subject by reference numeral 102. The subj ect is illustrated as a human by way of example only, and not to limit the scope or spirit of the invention in any way. Although, the apparatus is ultimately _g_ intended for treatment of brain disorders in humans, testing on laboratory animals or primates is not precluded from the scope of the present invention.
The apparatus 100 of the present invention includes a drug delivery means shown generally at reference numeral 104. The drug delivery means is implanted in the subject 102 for delivering at least one and possibly several drug solutions to a point of interest in the brain 106 of the subject 102. The drug delivery means 104 can be a cannula such as a mufti-port cannula having a plurality of ports, each port delivering the drug solution to a corresponding portion of the brain 106 or an intraventricular cannula fox delivering the drug solution to a substantial portion of 1 o the brain 102. Other types of cannulas known in the medical arts can also be used to deliver the chug solution to the point of interest in the brain 106. The drug delivery means 104 can alternatively be a catheter, a microdialysis probe, or other drug ejector device.
The drug delivery means 104 can be either implanted directly in the brain 106 of the subject or in the ventricular system of the subject. The implantation directly into the brain 106 is preferred because the time lag between the introduction of the drug solution and any effects therefrom are minimized. Cannulas, catheters, and microdialysis probes and the use and implantation thereof are well known in the medical arts and thus, a detailed description of them is omitted.
The apparatus 100 of the present invention also includes a drug driving means 108, such as a pump which is preferably subcutaneously disposed in the subject 102 for delivering the drug solutions to the drug delivery means 104.
The drug driving means and drug delivery means axe adapted to each other with appropriate tubing and fittings which are well known in the medical arts.
Preferably, the tubing and fittings are also subcutaneously disposed in the subject 102.
Referring now to Figure 3, the drug driving means 108 preferably also includes a drug reservoir 110 for holding a corresponding drug solution. The drug reservoir 110 is also preferably subcutaneously disposed in the subject 102 proximate to the drug driving means 108. The drug driving means 108 and drug reservoir are in fluid communication with each other by way of appropriate fittings and tubing 112 such that the drug driving means 108 can draw the drug solution from the drug to reservoir I 10 upon operation of the drug driving means 108.
The drug reservoir 110 can be initially filled With the drug solution prior to being implanted in the subj ect 102, in which case a surgical procedure is necessary if the drug reservoir needs refilling. However, the drug reservoir preferably includes a reservoir input 114 for supplying the drug solution to the drug 15 reservoir. The reservoir input 114 is in fluid communication with the drug reservoir through appropriate fittings and tubing 116 and externally accessible on a surface of the skin 118 of the subject 102 for periodic refilling. The reservoir input 114 is preferably a self sealing syringe fitting known in the medical arts but can be any type of fitting known in the medical arts which provides such external access.
2o Alternatively, the drug driving device can be a microcapillary device, nanotube, microtube, microfabricated pathway using electrokinetic force, or other components, and can be placed in body parts distant from the rest of the hybrid neuroprosthesis.
Referring back to Figures 1A, 1B, and 1C in combination, the apparatus 100 of the present invention also includes a recording electrode 120 implanted in the brain 106 for outputting an electrical signal characteristic of an electrical activity of the brain 102. Although implantation of the recording electrode 120 is described as being in the bxain 106, as shown in Figure 1 C, this phraseology is also intended to cover implantation of the recording electrode 120 on the brain 106 or in proximity to the surface of the brain 106, as shown in Figure 1A, depending upon l0 the type of recording electrode 120 utilized. The recording electrode 120 is preferably an EEG electrode which outputs a signal 121 (Figure 2) corresponding to the EEG
waves in the point of interest in the brain 106 per unit time. The recording electrode can be an extracellular recording electrode and can be complemented with a sensor to detect neurochemical signals such as neurotransmitter release or other molecular 15 events.
The apparatus 100 of the present invention further includes a microcontroller 122 which is preferably subcutaneously disposed in the subject for controlling the drug driving means 108 on the basis of the electrical signal 121 from the probe 120.
20 Refewing now to Figures 2 and 3, the microcontroller 122 preferably is accompanied by an electrical signal conditioner 132 for amplifying, filtering, and digitizing the recorded electrical signals from the brain and inputting the conditioned signals to the microcontroller. The electrical signal conditioner 132 includes an amplifier 124 for amplifying the signal 121 from the electrode 120 (see Figures 1 a and lc), a filter 126 for filtering the amplified signal 125, and an analog to digital (A/D) converter 128 for converting the filtered signal 127 to a digital signal 129. The s digital signal 129 is input to the microcontroller 122 which outputs a signal 121 a to control the operation of the drug driving means 108 (see Figures 1b and 3).
The filtered signal is a more reliable indication of the brain characteristic being sensed and does not include any noise from external sources, such as a cellular phone.
The microcontroller 122 is preferably a microprocessor, to analyze the to electrophysi~logical data stream from the electrical signal conditioner and regulate the drug delivery means accordingly. Alternatively, the microcontroller can be a digital signal processor (DSP), programmable logical array (PLA), a programmable logical device (PLD), or application-specific integrated circuit (ASIC). The microcontroller 122 is preferably equipped with a transmitter to transmit, preferably via a is communication system such as a radiotelemetry system, the analyzed electrophysiological signals to outside of the body for more advanced human and computer analysis. The microcontroller is yet preferably further equipped with a receiver to receive, preferably via a radiotelemetry or other communication system, human and computer commands from outside of the body.
2o Referring back to Figures 1A, 1B, and 1C in combination, the apparatus 100 of the present invention preferably also includes a power source 130, such as a battery, for supplying power to the drug driving means 108, microcontroller 122, and any other electrical components such as the electrical signal conditioner 132.
The battery 130 is also preferably subcutaneously disposed in the subject 102.
The power source 130 is preferably a NiMH or Lithium-ion battery which is also subcutaneously disposed in the subject and is rechargeable from the outside of the body from an electromagnetic or optical power source. Alternatively, the power source 130 is a subcutaneous current generator which taps the energy of the body.
The electrical signal conditioner 132 of the present invention preferably also further comprises a recorder disposed between the recording electrode 120 and the microcontroller 122 for recording the electrical signal 121 from the brain l0 106 and inputting the recorded signal to the microcontroller 122. The recordation of the signal 121 from the recording electrode 120 allows for future analysis of the signals over time and a comparison of such with other concurrent or subsequent observations such as behavior of the subject. The conditioner/recorder 132 is also preferably subcutaneously disposed in the subject 102.
is Some or all of the aforementioned components of the apparatus 100 of the present invention with the exception of the working ends of the recording electrode and drug delivery means are preferably housed in a single container subcutaneously disposed in the subject 102. Preferably, the recorder, battery, drug driving means, electrical signal conditioner, and microcontroller are all housed within 2o the container 134 in a compact miniature assembly. The container 134 is preferably a biocompatible elastomer case and more preferably is fabricated from medical grade silicon. Although the container 134 can be subcutaneously placed in a number of places in the subject, the preferable location for the subcutaneous placement of the container 134 is at the base of the brain 106 and back of the neck, as is illustrated in Figures 1A and 1C. Alternatively, the microcontroller, the drug driving means, the electrical signal conditioner/recorder 132, and the power source can be housed in individual containers, located in distant body parts under the skin, and are interconnected via subcutaneous tunneling.
The operation of the apparatus 100 of the present invention will now be described with reference to the Figures. The recording electrode 120 senses a characteristic of the brain, e.g., an electrical characteristic of the brain such as the rate of neuron cell firings per unit time, and outputs an electrical signal 121 corresponding to that characteristic. The conditioner/recorder 132 conditions and/or records the signals over time and passes the signal to the microcontroller 122 which analyzes the signal based on a certain criteria and controls the drug driving means 108 accordingly.
For instance, upon the detection by the recording electrode 120 that the rate of neuron cell firings has increased over a predetermined threshold (Figure 4B), the drug driving means 108 is controlled by the microcontroller 122 to turn on and deliver the drug solutions) from the drug reservoirs) 110. The drug driving means 108 may deliver a predetermined amount of chug solution or continue to deliver the drug solution until the detected characteristic returns to a level below the predetermined threshold (Figure 4A). The response to the drug solution is recorded by the conditioner/recorder I32 and analyzed.
The apparatus of the present invention can be used for the management of intractable temporal lobe epilepsies, which are currently treated by surgical removal of the epileptogenic tissue. The recording electrodes can monitor the electrophysiological activity of the epileptogenic focus (the area that generates seizures and contribute to interictal spiking), and from the recorded electrical signals the subcutaneously implanted microcontroller can recognize the initiation of an EEG
seizure and activate the drug driving means to deliver an antiepileptic drug solution directly into the pathophysiological tissue of the brain.
Another application for the apparatus of the present invention is the to intracerebroventricular administration of drug combinations, continuously adjusted by simultaneous electrophysiological monitoring, in patients with Alzheimer's disease.
In rats, chronic intracerebroventricular infusion of the phoshoprotein phosphatase inhibitor, okadaic acid, induces histopathological changes in the hippocampus and neocortex that resembles those that occur in Alzheimer's disease. This indicates that 15 the neural circuitries involved with Alzheimer's disease can be affected by drugs administered into the ventricles. If so, beneficial effects are also inducible in this disease via ventricular drug administrations, for example, with the use of a hybrid neuroprosthesis such as the apparatus of the present invention. The drug solution, ejected by the hybrid neuroprosthesis for the treatment of Alzheimer's disease may 20 contain several small molecules, peptides and proteins which act, in concert, on neurotransmitter receptors, ion channels, second messengers, genes, as well as on abnormal proteins such as hyperphosphorylated MAP tau in order to specifically increase the engram-creating firing rates of normal neurons while decrease the toxic load of abnormal neurons.
The apparatus of the present invention is also useful in the management of Parkinson's disease. There are those in the art who have reported clinical improvements in patients with Parkinson's disease following the grafting of human embryonic dopamine-rich mesencephalic tissue unilaterally into the putamen.
Thus, the treatment was achieved with implanting the dopamine-rich tissue at a single occasion, and without monitoring the electrical activity of the grafted area.
The apparatus of the present invention can offer multiple drug administrations into the putamen, regulated by local electrophysiological recordings. The viability of the hybrid neuroprosthesis strategy in the management of other brain disorders, especially in that of stroke, is also possible. The above brain disorders are given by way of examples only, and not to limit the scope of the invention in any way. Those of skill in the art will recognize that the apparatus of the present invention may be useful for a great number of brain disorders.
The apparatus of the present invention is useful for delivering drugs into a specific, pathophysiologically functioning brain site. However, brain disorders usually involve not one but several interconnected regions that function abnormally.
Therefore, localized drug deliveries may not be able to correct or reverse diffuse pathophysiological processes. This problem can be resolved with the use of a multiport cannula as the drug delivery means 104, which can release drugs along their axis into many brain sites, or intraventricular cannulas which can provide widespread drug administrations into the brain 106. Multiple drug reservoir-pump units, each having a cannula to a discrete brain area, can also be used to achieve widespread pharmacological effects in the brain.
Referring now to Figure 5, there are illustrated electroencephalogram (EEG) traces 502, 504 from the hippocampus of a rat, where the hippocampus was experimentally made epileptogenic. The epileptogenic focus was created in the hippocampus of the rat by the intrahippocampal injection of 150 units of penicillin G.
The upper trace 502 shows the EEG of the rat 16 hours after the creation of the focus, note the high amplitude epileptiform interictal spikes 502a on the upper trace l0 recording 502. The lower trace 504 shows the hippocampal EEG activity of the rat one minute after the injection of pentobarbital, an antiepileptic drug, into the epileptogenic focus. Note the complete cessation of the epileptiform electrical activity in the lower trace recording 504. This experimental model demonstrates the correctness of the hybrid neuroprosthesis concept, namely, that the abnormal activity 15 of a dysfunctioning brain area can be corrected by the injection of the proper drug into the area of dysfunction.
In summary, the apparatus of the present invention uses an intracerebrally implanted electrode, cannula units, connected to a subcutaneausly implanted rizicrocontroller which analyzes the recorded electrophysiological signals 20 and activates a nearby drug driving means, such as a pump, to deliver drug solutions through a drug delivery means 104 such as a cannula. In this way, finely controlled intracerebral drug deliveries into a malfunctioning brain area can. be achieved at the moment when abnormal electrical activity occurs in the malfunctioning brain area.
Such an apparatus is a useful addition to the repertoire of future neuroprosthesis.
While there has been shown and described what is considered to be preferred embodiments of the invention, it will, of course, be understood that various modifications and changes in form or detail could readily be made without departing from the spirit of the invention. For instance, it should be apparent to those skilled in the medical arts that a plurality of recording electrodes 120 and drug delivery means 104 can be utilized without departing from the scope or spirit of the present invention.
In such a configuration, each of the plurality of recording electrodes 120 can input a signal to a single microcontroller 122 which can control a separate drug driving means 108 for each drug delivery means 104 (i.e., each of a plurality of cannulas and/or catheters). Alternatively, a single drug driving means I08 can be used to deliver the drug solution to all of the drug delivery means 104. It is also understood that the recording electrode can be readily complemented with a neurochemical 1S sensor to provide, after appropriate molecule concentration - electrical current conversion, additional electrical input to the microcontroller.
It is therefore intended that the invention be not limited to the exact forms described and illustrated, but should be construed to cover all modifications that may fall within the scope of the appended claims.
TREATMENT OF BRAIN DISORDERS
The present invention relates generally to the treatment of brain disorders, and more particularly, to a hybrid neuropr0sthesis apparatus implanted subcutaneously in a human subject.
At the dawn of the year 2000, effective therapy is still unavailable for the treatment of Alzheimer's disease and other degenerative disorders, stroke is still the third leading cause of death in the United States after heart disease and cancer, and currently marketed drugs are still ineffective in about 60% of patients with complex partial seizures. These few examples may demonstrate that the challenges for neurology and psychiatry in the new century will be as enormous as the achievements of these medical fields in the past one. New therapeutic strategies are needed, which capitalize on the progress in drug research, molecular biology, computer technology and electronics. Constructing neuroprosthetic devices is part of these efforts.
The first generation of successful neuroprosthesis included diaphragm pacing devices to stimulate the phrenic nerve in patients with respiratory paralysis, the Neurocybernetic Prosthesis for seizure control via vagus nerve stimulation, and 2o cochlear implants for acoustic name stimulation in individuals with hearing loss. A
second generation of neuroprostheses, designed to restore sensory and motor functions are under development in various laboratories. A common feature of these existing and experimental neuroprosthetic devices is that they stimulate the neural tissue electrically.
However, the neurons of the brain are not merely living electronic machines. While these cells indeed transmit information to other neurons with the use of purely electrical tools referred to as "action potentials", the generation and spacing of action potentials are regulated by molecular mechanisms. In fact, these mechanisms are sophisticated interplays of a large number of infra- and extracellular molecular systems. Thus, the neurons work as molecular-electronic computers, as they process their inputs with molecular mechanisms in order to generate electrical outputs.
The hybrid neuroprosthesis device of the present invention is essentially the translation of the dual: molecular-electronic nature of neurons into a medical device. The term "hybrid neuroprosthesis" refers to a subcutaneously implanted miniature apparatus which simultaneously acts as an electrophysiological data recorder and a drug delivery means such as a pump. This allow it to monitor the electrical activity of a dysfunctioning brain area and to correct the dysfunction by delivering drugs into the environment of the abnormal neurons.
Accordingly, the hybrid neuroprosthesis of the present invention fundamentally differs from all prior neuroprostheses, as the hybrid neuroprosthesis aims to correct neural dysfunctions pharmacologically, and not electrically.
The advantage of the hybrid neuroprosthesis approach is that with drugs neuron-and synapse-specific actions can be achieved, which is difficult to accomplish with electrical stimulations.
The hybrid neuroprosthesis of the present invention also differs from the intracerebral drug delivery technologies of the prior art. No prior intracerebral drug delivery systems, including drug-loaded ethylene vinyl acetate copolymer (EVAc) rods, are able to monitor the electrical activity of the targeted brain tissue. As a consequence, no feed-back is obtained from the targeted tissue. This may lead to too high, therefore damaging, or too low, therefore ineffective, drug concentrations.
No prior intracerebral drug delivery systems can apply the drug solutions periodically, only when this intervention is necessary.
Indeed, a device is needed which is able to monitor the electrical activity of a dysfunctioning brain area without interfering with the patient's daily Life, yet also being able to deliver drugs into the dysfunctioning brain area:
precisely when it is necessary. The hybrid neuroprosthesis device of the present invention satisfies this need, especially since the device can also be extended to monitoring not only the electrical but also the neurochemical activity of the dysfunctioning brain area and to deliver drugs into this area in response to either the neurochemical signals, or the electrical signals, or both.
The present invention provides an apparatus and methods for the treatment of brain disorders which overcomes the problems of the prior art.
The present invention also provides an apparatus and methods for the treatment of brain disorders which stimulates brain tissue by pharmacological stimulation.
Further, the present invention provides an apparatus and methods for the treatment of brain disorders which can be used in controlled human studies.
Still further, the present invention provides an apparatus and methods for the treatment of brain disorders for analyzing neuronal firing in natural circumstances, during behavior.
Still even further, the present invention provides an apparatus and methods for the treatment of brain disorders in which a delivered eh-ug solution does not affect the cells of the whole body which can drastically change the subject's behavior.
to In addition, the present invention provides an apparatus and methods for the treatment of brain disorders which regulates intracerebral drug delivery.
Accordingly, an apparatus for the treatment of brain disorders in a subject is provided. The apparatus comprises: a drug delivery means implanted in the subject for delivering at least one drug solution to the brain of the subject;
a drug 15 driving means that drives the at least one dmg solution to the drug delivery means; a recording electrode implanted in the brain for outputting an electrical signal characteristic of an electrical activity of the brain; and a microcontroller for controlling the drug driving means on the basis of the electrical signal.
Preferably, the entire apparatus is subcutaneously disposed in the subject. Preferably, the recording 20 electrode is complemented with a sensor to detect neurochemical signals such as neurotransmitter release or other molecular events. Alternatively, the recording electrode is replaced by a neurochemical sensor.
The drug delivery means is preferably a cannula, such as a mufti-port cannula having a plurality of ports, each port delivering the drug solution to a corresponding portion of the brain or an intraventricular cannula for delivering the drug solution to a substantial portion of the brain. Alternatively, the drug delivery means can be a catheter, microdialysis probe, or other drug ejector device.
The drug delivery means is implanted in the brain of the subject or in the ventricular system of the subj ect.
The drug driving means is preferably a pump, that includes a drug reservoir for holding the at least one drug solution and which is also preferably subcutaneously disposed in the subject and is externally accessible on the surface of the skin for periodic refilling. Alternatively, the drug driving device can be a microcapillary device, nanotube, microtube, microfabricated pathway using electrokinetic force, or other components.
The apparatus preferably further comprises an electrical signal conditioner disposed between the recording electrode and the microcontroller for amplifying, filtering and digitizing the recorded electrical signals from the brain and inputting the conditioned signals to the microcontroller, wherein the electrical signal conditioner is also preferably subcutaneously disposed in the subject.
The microcontroller is preferably equipped with a microprocessor, to 2o analyze the electrophysiological data stream from the electrical signal conditioner and regulate the drug driving means accordingly. Alternatively, the microcontroller can be a digital signal processor (DSP), a programmable logical array (PLA), a programmable logical device (PLD), an application-specific integrated circuit (ASIC), or other similar device. The processor can be equipped with a transmitter to transmit, preferably via a communication system, the analyzed electrophysiological signals to outside of the body for more advanced human and computer analysis. The processor is preferably further equipped with a receiver to receive, preferably via a communication system, human and computer commands from outside of the body.
The apparatus still further comprises a power source, such as a battery, for supplying power to the drug driving device, the microcontroller and the electrical signal conditioner. The battery is preferably a NiMH or Lithium-ion battery which is l0 also subcutaneously disposed in the subject and is rechargeable from the outside of the body from an electromagnetic or optical power source. Alternatively, the power source is a subcutaneous current generator.
In a preferred configuration of the apparatus, the microcontroller, the drug driving means, the electrical signal conditioner and the battery are housed in a 15 single container subcutaneously disposed in the subject. The container is preferably an elastomer case fabricated from medical grade silicon and is subcutaneously disposed in the subject at the base of the brain and back of the neck.
Alternatively, the microcontroller, the drug driving means, the electrical signal conditioner and the power source can be housed in individual containers, located in distant body parts 2o under the skin, and are interconnected via subcutaneous tunneling.
Also provided are methods for the treatment of brain disorders with the apparatus of the present invention.
These and other features, aspects, and advantages of the apparatus and methods of the present invention will become better understood with regard to the following description, appended claims, and accompanying drawings where:
Figure 1A illustrates the hybrid neuroprosthesis of the present invention subcutaneously disposed in a subject.
Figure 1B illustrates an enlarged view of the hybrid neuroprosthesis of Fig. 1 A.
Figure 1C illustrates an alternative configuration of the hybrid neuroprosthesis of the present invention.
to Figure 2 illustrates the schematic diagram of a preferred implementation of the electrical signal conditioner - microcontroller unit of Figure 1B.
Figure 3 illustrates an alternative version of the hybrid neuroprosthesis of Fig. 1 B.
15 Figures 4A and 4B illustrate normal and abnormal neuronal firing patterns in the rat hippocampus, respectively.
Figure 5 presents an experimental model for the hybrid neuroprosthesis concept, showing EEG recordings from the epileptogenic hippocampus of a rat before and after the microinjection of an antiepileptic drug solution directly into the 20 dysfunctioning hippocampal area.
Although this invention is applicable to numerous and various types of subjects, it is particularly useful in the environment of human subjects.
Therefore, without limiting the applicability of the invention to human subjects, the apparatus and methods of the present invention will be described in such an environment.
The term "hybrid neuroprosthesis" as used herein refers to a microprocessor-controlled, intracerebrally implanted drug delivery device, in which the timing and duration of the drug deliveixes are determined by the implanted brain tissue's own electrical activity. Thus, the device is a "hybrid" of pharmacological and electrophysiological instruments. The pharmacological components are: (1) a drug delivery device such as a cannula, catheter, or microdialysis probe chronically implanted in the ventricular system or in the brain tissue, and (2) a miniature, l0 subcutaneously placed drug reservoir/drug driving means, which can be periodically refilled. The electrophysiological components are: (1) a recording electrode chronically implanted in the brain, and (2) a miniature, subcutaneously placed electrical signal conditioner. A processor, alternatively referred to as a microcontroller, placed in close proximity to these components, both analyzes the 15 electrophysiological data and controls the drug reservoir/drug driving means. All of these components are powered by a nearby power supply, such as a battery, and sealed in a biocompatible case.
Referring now to Figures 1A, 1B, and 1C in combination, there is illustrated an apparatus for the treatment of brain disorders in a subject, the apparatus 2o being generally referred to by reference numeral 100, the subject by reference numeral 102. The subj ect is illustrated as a human by way of example only, and not to limit the scope or spirit of the invention in any way. Although, the apparatus is ultimately _g_ intended for treatment of brain disorders in humans, testing on laboratory animals or primates is not precluded from the scope of the present invention.
The apparatus 100 of the present invention includes a drug delivery means shown generally at reference numeral 104. The drug delivery means is implanted in the subject 102 for delivering at least one and possibly several drug solutions to a point of interest in the brain 106 of the subject 102. The drug delivery means 104 can be a cannula such as a mufti-port cannula having a plurality of ports, each port delivering the drug solution to a corresponding portion of the brain 106 or an intraventricular cannula fox delivering the drug solution to a substantial portion of 1 o the brain 102. Other types of cannulas known in the medical arts can also be used to deliver the chug solution to the point of interest in the brain 106. The drug delivery means 104 can alternatively be a catheter, a microdialysis probe, or other drug ejector device.
The drug delivery means 104 can be either implanted directly in the brain 106 of the subject or in the ventricular system of the subject. The implantation directly into the brain 106 is preferred because the time lag between the introduction of the drug solution and any effects therefrom are minimized. Cannulas, catheters, and microdialysis probes and the use and implantation thereof are well known in the medical arts and thus, a detailed description of them is omitted.
The apparatus 100 of the present invention also includes a drug driving means 108, such as a pump which is preferably subcutaneously disposed in the subject 102 for delivering the drug solutions to the drug delivery means 104.
The drug driving means and drug delivery means axe adapted to each other with appropriate tubing and fittings which are well known in the medical arts.
Preferably, the tubing and fittings are also subcutaneously disposed in the subject 102.
Referring now to Figure 3, the drug driving means 108 preferably also includes a drug reservoir 110 for holding a corresponding drug solution. The drug reservoir 110 is also preferably subcutaneously disposed in the subject 102 proximate to the drug driving means 108. The drug driving means 108 and drug reservoir are in fluid communication with each other by way of appropriate fittings and tubing 112 such that the drug driving means 108 can draw the drug solution from the drug to reservoir I 10 upon operation of the drug driving means 108.
The drug reservoir 110 can be initially filled With the drug solution prior to being implanted in the subj ect 102, in which case a surgical procedure is necessary if the drug reservoir needs refilling. However, the drug reservoir preferably includes a reservoir input 114 for supplying the drug solution to the drug 15 reservoir. The reservoir input 114 is in fluid communication with the drug reservoir through appropriate fittings and tubing 116 and externally accessible on a surface of the skin 118 of the subject 102 for periodic refilling. The reservoir input 114 is preferably a self sealing syringe fitting known in the medical arts but can be any type of fitting known in the medical arts which provides such external access.
2o Alternatively, the drug driving device can be a microcapillary device, nanotube, microtube, microfabricated pathway using electrokinetic force, or other components, and can be placed in body parts distant from the rest of the hybrid neuroprosthesis.
Referring back to Figures 1A, 1B, and 1C in combination, the apparatus 100 of the present invention also includes a recording electrode 120 implanted in the brain 106 for outputting an electrical signal characteristic of an electrical activity of the brain 102. Although implantation of the recording electrode 120 is described as being in the bxain 106, as shown in Figure 1 C, this phraseology is also intended to cover implantation of the recording electrode 120 on the brain 106 or in proximity to the surface of the brain 106, as shown in Figure 1A, depending upon l0 the type of recording electrode 120 utilized. The recording electrode 120 is preferably an EEG electrode which outputs a signal 121 (Figure 2) corresponding to the EEG
waves in the point of interest in the brain 106 per unit time. The recording electrode can be an extracellular recording electrode and can be complemented with a sensor to detect neurochemical signals such as neurotransmitter release or other molecular 15 events.
The apparatus 100 of the present invention further includes a microcontroller 122 which is preferably subcutaneously disposed in the subject for controlling the drug driving means 108 on the basis of the electrical signal 121 from the probe 120.
20 Refewing now to Figures 2 and 3, the microcontroller 122 preferably is accompanied by an electrical signal conditioner 132 for amplifying, filtering, and digitizing the recorded electrical signals from the brain and inputting the conditioned signals to the microcontroller. The electrical signal conditioner 132 includes an amplifier 124 for amplifying the signal 121 from the electrode 120 (see Figures 1 a and lc), a filter 126 for filtering the amplified signal 125, and an analog to digital (A/D) converter 128 for converting the filtered signal 127 to a digital signal 129. The s digital signal 129 is input to the microcontroller 122 which outputs a signal 121 a to control the operation of the drug driving means 108 (see Figures 1b and 3).
The filtered signal is a more reliable indication of the brain characteristic being sensed and does not include any noise from external sources, such as a cellular phone.
The microcontroller 122 is preferably a microprocessor, to analyze the to electrophysi~logical data stream from the electrical signal conditioner and regulate the drug delivery means accordingly. Alternatively, the microcontroller can be a digital signal processor (DSP), programmable logical array (PLA), a programmable logical device (PLD), or application-specific integrated circuit (ASIC). The microcontroller 122 is preferably equipped with a transmitter to transmit, preferably via a is communication system such as a radiotelemetry system, the analyzed electrophysiological signals to outside of the body for more advanced human and computer analysis. The microcontroller is yet preferably further equipped with a receiver to receive, preferably via a radiotelemetry or other communication system, human and computer commands from outside of the body.
2o Referring back to Figures 1A, 1B, and 1C in combination, the apparatus 100 of the present invention preferably also includes a power source 130, such as a battery, for supplying power to the drug driving means 108, microcontroller 122, and any other electrical components such as the electrical signal conditioner 132.
The battery 130 is also preferably subcutaneously disposed in the subject 102.
The power source 130 is preferably a NiMH or Lithium-ion battery which is also subcutaneously disposed in the subject and is rechargeable from the outside of the body from an electromagnetic or optical power source. Alternatively, the power source 130 is a subcutaneous current generator which taps the energy of the body.
The electrical signal conditioner 132 of the present invention preferably also further comprises a recorder disposed between the recording electrode 120 and the microcontroller 122 for recording the electrical signal 121 from the brain l0 106 and inputting the recorded signal to the microcontroller 122. The recordation of the signal 121 from the recording electrode 120 allows for future analysis of the signals over time and a comparison of such with other concurrent or subsequent observations such as behavior of the subject. The conditioner/recorder 132 is also preferably subcutaneously disposed in the subject 102.
is Some or all of the aforementioned components of the apparatus 100 of the present invention with the exception of the working ends of the recording electrode and drug delivery means are preferably housed in a single container subcutaneously disposed in the subject 102. Preferably, the recorder, battery, drug driving means, electrical signal conditioner, and microcontroller are all housed within 2o the container 134 in a compact miniature assembly. The container 134 is preferably a biocompatible elastomer case and more preferably is fabricated from medical grade silicon. Although the container 134 can be subcutaneously placed in a number of places in the subject, the preferable location for the subcutaneous placement of the container 134 is at the base of the brain 106 and back of the neck, as is illustrated in Figures 1A and 1C. Alternatively, the microcontroller, the drug driving means, the electrical signal conditioner/recorder 132, and the power source can be housed in individual containers, located in distant body parts under the skin, and are interconnected via subcutaneous tunneling.
The operation of the apparatus 100 of the present invention will now be described with reference to the Figures. The recording electrode 120 senses a characteristic of the brain, e.g., an electrical characteristic of the brain such as the rate of neuron cell firings per unit time, and outputs an electrical signal 121 corresponding to that characteristic. The conditioner/recorder 132 conditions and/or records the signals over time and passes the signal to the microcontroller 122 which analyzes the signal based on a certain criteria and controls the drug driving means 108 accordingly.
For instance, upon the detection by the recording electrode 120 that the rate of neuron cell firings has increased over a predetermined threshold (Figure 4B), the drug driving means 108 is controlled by the microcontroller 122 to turn on and deliver the drug solutions) from the drug reservoirs) 110. The drug driving means 108 may deliver a predetermined amount of chug solution or continue to deliver the drug solution until the detected characteristic returns to a level below the predetermined threshold (Figure 4A). The response to the drug solution is recorded by the conditioner/recorder I32 and analyzed.
The apparatus of the present invention can be used for the management of intractable temporal lobe epilepsies, which are currently treated by surgical removal of the epileptogenic tissue. The recording electrodes can monitor the electrophysiological activity of the epileptogenic focus (the area that generates seizures and contribute to interictal spiking), and from the recorded electrical signals the subcutaneously implanted microcontroller can recognize the initiation of an EEG
seizure and activate the drug driving means to deliver an antiepileptic drug solution directly into the pathophysiological tissue of the brain.
Another application for the apparatus of the present invention is the to intracerebroventricular administration of drug combinations, continuously adjusted by simultaneous electrophysiological monitoring, in patients with Alzheimer's disease.
In rats, chronic intracerebroventricular infusion of the phoshoprotein phosphatase inhibitor, okadaic acid, induces histopathological changes in the hippocampus and neocortex that resembles those that occur in Alzheimer's disease. This indicates that 15 the neural circuitries involved with Alzheimer's disease can be affected by drugs administered into the ventricles. If so, beneficial effects are also inducible in this disease via ventricular drug administrations, for example, with the use of a hybrid neuroprosthesis such as the apparatus of the present invention. The drug solution, ejected by the hybrid neuroprosthesis for the treatment of Alzheimer's disease may 20 contain several small molecules, peptides and proteins which act, in concert, on neurotransmitter receptors, ion channels, second messengers, genes, as well as on abnormal proteins such as hyperphosphorylated MAP tau in order to specifically increase the engram-creating firing rates of normal neurons while decrease the toxic load of abnormal neurons.
The apparatus of the present invention is also useful in the management of Parkinson's disease. There are those in the art who have reported clinical improvements in patients with Parkinson's disease following the grafting of human embryonic dopamine-rich mesencephalic tissue unilaterally into the putamen.
Thus, the treatment was achieved with implanting the dopamine-rich tissue at a single occasion, and without monitoring the electrical activity of the grafted area.
The apparatus of the present invention can offer multiple drug administrations into the putamen, regulated by local electrophysiological recordings. The viability of the hybrid neuroprosthesis strategy in the management of other brain disorders, especially in that of stroke, is also possible. The above brain disorders are given by way of examples only, and not to limit the scope of the invention in any way. Those of skill in the art will recognize that the apparatus of the present invention may be useful for a great number of brain disorders.
The apparatus of the present invention is useful for delivering drugs into a specific, pathophysiologically functioning brain site. However, brain disorders usually involve not one but several interconnected regions that function abnormally.
Therefore, localized drug deliveries may not be able to correct or reverse diffuse pathophysiological processes. This problem can be resolved with the use of a multiport cannula as the drug delivery means 104, which can release drugs along their axis into many brain sites, or intraventricular cannulas which can provide widespread drug administrations into the brain 106. Multiple drug reservoir-pump units, each having a cannula to a discrete brain area, can also be used to achieve widespread pharmacological effects in the brain.
Referring now to Figure 5, there are illustrated electroencephalogram (EEG) traces 502, 504 from the hippocampus of a rat, where the hippocampus was experimentally made epileptogenic. The epileptogenic focus was created in the hippocampus of the rat by the intrahippocampal injection of 150 units of penicillin G.
The upper trace 502 shows the EEG of the rat 16 hours after the creation of the focus, note the high amplitude epileptiform interictal spikes 502a on the upper trace l0 recording 502. The lower trace 504 shows the hippocampal EEG activity of the rat one minute after the injection of pentobarbital, an antiepileptic drug, into the epileptogenic focus. Note the complete cessation of the epileptiform electrical activity in the lower trace recording 504. This experimental model demonstrates the correctness of the hybrid neuroprosthesis concept, namely, that the abnormal activity 15 of a dysfunctioning brain area can be corrected by the injection of the proper drug into the area of dysfunction.
In summary, the apparatus of the present invention uses an intracerebrally implanted electrode, cannula units, connected to a subcutaneausly implanted rizicrocontroller which analyzes the recorded electrophysiological signals 20 and activates a nearby drug driving means, such as a pump, to deliver drug solutions through a drug delivery means 104 such as a cannula. In this way, finely controlled intracerebral drug deliveries into a malfunctioning brain area can. be achieved at the moment when abnormal electrical activity occurs in the malfunctioning brain area.
Such an apparatus is a useful addition to the repertoire of future neuroprosthesis.
While there has been shown and described what is considered to be preferred embodiments of the invention, it will, of course, be understood that various modifications and changes in form or detail could readily be made without departing from the spirit of the invention. For instance, it should be apparent to those skilled in the medical arts that a plurality of recording electrodes 120 and drug delivery means 104 can be utilized without departing from the scope or spirit of the present invention.
In such a configuration, each of the plurality of recording electrodes 120 can input a signal to a single microcontroller 122 which can control a separate drug driving means 108 for each drug delivery means 104 (i.e., each of a plurality of cannulas and/or catheters). Alternatively, a single drug driving means I08 can be used to deliver the drug solution to all of the drug delivery means 104. It is also understood that the recording electrode can be readily complemented with a neurochemical 1S sensor to provide, after appropriate molecule concentration - electrical current conversion, additional electrical input to the microcontroller.
It is therefore intended that the invention be not limited to the exact forms described and illustrated, but should be construed to cover all modifications that may fall within the scope of the appended claims.
Claims (46)
1. An apparatus for the treatment of brain disorders in a subject, the apparatus comprising:
a drug delivery means implanted in the subject for delivering at least one drug solution to the brain of the subject;
a drug driving means for delivering the at least one drug solution to the drug delivery means;
a recording electrode implanted in the brain for outputting an electrical signal characteristic of an electrical activity of the brain; and a microcontroller controlling the drug driving means on the basis of the electrical signal.
a drug delivery means implanted in the subject for delivering at least one drug solution to the brain of the subject;
a drug driving means for delivering the at least one drug solution to the drug delivery means;
a recording electrode implanted in the brain for outputting an electrical signal characteristic of an electrical activity of the brain; and a microcontroller controlling the drug driving means on the basis of the electrical signal.
2. The apparatus of claim 1, wherein the drug driving means is subcutaneously disposed in the subject.
3. The apparatus of claim 1 or 2, wherein the microcontroller is subcutaneously disposed in the subject.
4. The apparatus of any one of claims 1-3, wherein the drug delivery means is a cannula.
5. The apparatus of claim 4, wherein the cannula is a multi-port cannula having a plurality of ports, each port delivering the at least one drug solution to a corresponding portion of the brain.
6. The apparatus of claim 4, wherein the cannula is a intraventricular cannula for delivering the at least one drug solution to a substantial portion of the brain.
7. The apparatus of any one of claims 1-3, wherein the drug delivery means is a catheter.
8. The apparatus of any one of claims 1-3, wherein the drug delivery means is a microdialysis probe.
9. The apparatus of any one of claims 1-8, wherein the drug delivery means is implanted in the brain of the subject.
10. The apparatus of any one of claims 1-8, wherein the drug delivery means is implanted in the ventricular system of the subject.
11. The apparatus of any one of claims 1-10, wherein the drug driving means further includes a drug reservoir for holding the drug solution.
12. The apparatus of claim 11, wherein the drug reservoir is subcutaneously disposed in the subject.
13. The apparatus of claim 12, further comprising a reservoir input for supplying the at least one drug solution to the drug reservoir, the reservoir input being in fluid communication with the drug reservoir and externally accessible on a surface of the skin of the subject.
14. The apparatus of claim 13, wherein the reservoir input is a self-sealing syringe fitting.
15. The apparatus of any one of claims 1-14, wherein the recording electrode is an EEG electrode.
16. The apparatus of any one of claims 1-15, wherein the recording electrode outputs a signal corresponding to a rate of neuron cell firings per unit time.
17. The apparatus of any one of claims 1-16, further comprising an electrical signal conditioner disposed between the recording electrode and the microcontroller for recording the signal from the brain and inputting the recorded signal to the microcontroller.
18. The apparatus of claim 17, wherein the electrical signal conditioner is subcutaneously disposed in the subject.
19. The apparatus of any one of claims 1-18, wherein the microcontroller further comprises an electrical signal conditioner having an amplifier for amplifying the signal, a filter for filtering the noise from the analog signal, and an analog to digital converter for converting the filtered analog signal to a digital signal, the digital signal being input to the microcontroller.
20. The apparatus of any one of claims 1-19, further comprising a power source for supplying power to the drug driving means and microcontroller.
21. The apparatus of claim 20, wherein the power source is a rechargeable battery.
22. The apparatus of claim 21, wherein the battery is subcutaneously disposed in the subject.
23. The apparatus of any one of claims 1-22, further comprising a container subcutaneously disposed in the subject for housing the microcontroller and drug driving means.
24. The apparatus of claim 18, further comprising a container subcutaneously disposed in the subject for housing the microcontroller, drug driving means, and electrical signal conditioner.
25. The apparatus of claim 22, further comprising a container subcutaneously disposed in the subject for housing the microcontroller, drug driving means, and battery.
26. The apparatus of claim 23, wherein the container is an elastomer case.
27. The apparatus of claim 26, wherein the elastomer case is fabricated from medical grade silicon,
28. The apparatus of any one of claims 1-27, further comprising a neurochemical sensor fox detecting neurochemical signals of the brain and converting the neurochemical signals to electrical signals, the microcontroller also analyzing the converted electrical signals from the neurochemical sensor and controlling the drug driving means on the basis thereof
29. The apparatus of any one of claims 1-28, further comprising a communication system for allowing wireless data exchange from the microcontroller to a remote location.
30. A method for treating brain disorders in a subject, the method comprising the steps of:
implanting a drug delivery means in the subject for delivering at least one drug solution to the brain of the subject;
subcutaneously disposing a drug driving means in the subject for delivering the at least one drug solution to the drug delivery means;
implanting a recording electrode in the brain of the subject for outputting an electrical signal characteristic of an electrical activity of the brain;
subcutaneously disposing a microcontroller in the subject; and controlling the drug driving means on the basis of the electrical signal to deliver the at least one drug solution to the brain of the subject.
implanting a drug delivery means in the subject for delivering at least one drug solution to the brain of the subject;
subcutaneously disposing a drug driving means in the subject for delivering the at least one drug solution to the drug delivery means;
implanting a recording electrode in the brain of the subject for outputting an electrical signal characteristic of an electrical activity of the brain;
subcutaneously disposing a microcontroller in the subject; and controlling the drug driving means on the basis of the electrical signal to deliver the at least one drug solution to the brain of the subject.
31. The method of claim 30, wherein the drug delivery means is a mufti-port cannula having a plurality of ports, the method further comprising the step of delivering the drug solution to each port corresponding to a different portion of the brain.
32. The method of claim 30, wherein the chug delivery means is a intraventricular cannula, the method further comprising the step of delivering the drug solution to a substantial portion of the brain.
33. The method of any one of claims 30-32, wherein the implanting of the drug delivery means comprises implanting the drug delivery means in the brain of the subject.
34. The method of any one of claims 30-32, wherein the implanting of the drug delivery means comprises implanting the drug delivery means in the ventricular system of the subject.
35. The method of any one of claims 30-34, further comprising the step of subcutaneously disposing a drug reservoir in the subject for holding the at least one drug solution.
36. The method of claim 35, wherein the step of subcutaneously disposing a drug reservoir in the subject further comprises disposing a reservoir input in fluid communication with the drug reservoir on a surface of the skin of the subject and further comprising the step of supplying the drug solution to the drug reservoir through the reservoir input.
37. The method of any one of claims 30-36, further comprising the step of outputting the electrical signal corresponding to a rata of neuron cell firings per unit time.
38. The method of any one of claims 30-37, further comprising the step of subcutaneously disposing a recorder in the subject between the recording electrode and the microcontroller for recording the signal from the brain and inputting the recorded signal to the microcontroller.
39. The method of any one of claims 30-38, further comprising the steps of amplifying the signal, filtering the analog signal, and converting the filtered analog signal into digital signal being input to the microcontroller.
40. The method of any one of claims 30-39, further comprising the step of subcutaneously disposing a battery in the subject for supplying power to the drug driving means and microcontroller.
41. The method of any one of claims 30-40, further comprising the steps of housing the microcontroller and drug driving means in a container and subcutaneously disposing the container in the subject.
42. The method of claim 41, wherein the step of subcutaneously disposing the container in the subject comprises subcutaneously disposing the container at the base of the brain and back of the neck.
43. The method of any one of claims 30-42, wherein the controlling step comprises the step of supplying power to the drug driving means to deliver drug solution to the brain of the subject when the electrical signal reaches a predetermined threshold.
44. The method of claim 43, wherein the supplying step comprises the step of continuing to supply power to the drug driving means for a predetermined time to deliver a predetermined amount of drug solution to the brain.
45. The method of claim 43, wherein the supplying step comprises the step of continuing to supply power to the drug driving means until the signal retracts from the predetermined threshold.
46. The method of any one of claims 30-45, wherein the brain disorder is selected from a group consisting of stroke, epilepsy, Alzheimer's disease, and Parkinson's disease.
brain area to the microcontroller. The components of the apparatus are encapsulated in medical grade silicon.
brain area to the microcontroller. The components of the apparatus are encapsulated in medical grade silicon.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/634,172 US6497699B1 (en) | 2000-08-09 | 2000-08-09 | Hybrid neuroprosthesis for the treatment of brain disorders |
US09/634,172 | 2000-08-09 | ||
PCT/US2001/024870 WO2002011703A1 (en) | 2000-08-09 | 2001-08-09 | Hybrid neuroprosthesis for the treatment of brain disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2418070A1 CA2418070A1 (en) | 2002-02-14 |
CA2418070C true CA2418070C (en) | 2010-06-29 |
Family
ID=24542713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2418070A Expired - Fee Related CA2418070C (en) | 2000-08-09 | 2001-08-09 | Hybrid neuroprosthesis for the treatment of brain disorders |
Country Status (7)
Country | Link |
---|---|
US (1) | US6497699B1 (en) |
EP (1) | EP1311245A4 (en) |
JP (1) | JP2004505675A (en) |
AU (1) | AU8119001A (en) |
CA (1) | CA2418070C (en) |
HU (1) | HUP0301698A2 (en) |
WO (1) | WO2002011703A1 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7305268B2 (en) | 2000-07-13 | 2007-12-04 | Northstar Neurscience, Inc. | Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators |
US7831305B2 (en) | 2001-10-15 | 2010-11-09 | Advanced Neuromodulation Systems, Inc. | Neural stimulation system and method responsive to collateral neural activity |
US7756584B2 (en) | 2000-07-13 | 2010-07-13 | Advanced Neuromodulation Systems, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7108680B2 (en) * | 2002-03-06 | 2006-09-19 | Codman & Shurtleff, Inc. | Closed-loop drug delivery system |
GB2389791B (en) | 2002-04-30 | 2006-12-13 | Steven Gill | Implantable drug delivery pump |
US7867193B2 (en) | 2004-01-29 | 2011-01-11 | The Charles Stark Draper Laboratory, Inc. | Drug delivery apparatus |
US7236830B2 (en) * | 2002-12-10 | 2007-06-26 | Northstar Neuroscience, Inc. | Systems and methods for enhancing or optimizing neural stimulation therapy for treating symptoms of Parkinson's disease and/or other movement disorders |
US20050075680A1 (en) | 2003-04-18 | 2005-04-07 | Lowry David Warren | Methods and systems for intracranial neurostimulation and/or sensing |
CN1781019A (en) * | 2003-03-12 | 2006-05-31 | 萨马里坦药品公司 | Animal model simulating neurologic disease |
JP2006525827A (en) * | 2003-05-29 | 2006-11-16 | レニショウ パブリック リミテッド カンパニー | Implantable pump |
WO2005011805A2 (en) | 2003-08-01 | 2005-02-10 | Northstar Neuroscience, Inc. | Apparatus and methods for applying neural stimulation to a patient |
US7686780B2 (en) * | 2003-09-26 | 2010-03-30 | New York University | System and method for correction of intracerebral chemical imbalances |
US7867194B2 (en) | 2004-01-29 | 2011-01-11 | The Charles Stark Draper Laboratory, Inc. | Drug delivery apparatus |
AU2005275209B2 (en) | 2004-07-15 | 2010-06-24 | Advanced Neuromodulation Systems, Inc. | Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy |
WO2006040765A1 (en) * | 2004-10-12 | 2006-04-20 | Closed Loop Therapies Ltd. | Methods and implantable devices for treating supraventricular arrhythmias |
US20060106430A1 (en) * | 2004-11-12 | 2006-05-18 | Brad Fowler | Electrode configurations for reducing invasiveness and/or enhancing neural stimulation efficacy, and associated methods |
US8309057B2 (en) | 2005-06-10 | 2012-11-13 | The Invention Science Fund I, Llc | Methods for elevating neurotrophic agents |
US9042974B2 (en) * | 2005-09-12 | 2015-05-26 | New York University | Apparatus and method for monitoring and treatment of brain disorders |
US7729773B2 (en) * | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
WO2007075477A2 (en) * | 2005-12-19 | 2007-07-05 | University Of Florida | Closed-loop state-dependent seizure prevention systems |
US10850235B2 (en) | 2006-10-09 | 2020-12-01 | Minnetronix, Inc. | Method for filtering cerebrospinal fluid (CSF) including monitoring CSF flow |
US10632237B2 (en) | 2006-10-09 | 2020-04-28 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
JP2010505556A (en) | 2006-10-09 | 2010-02-25 | ニューロフルーディクス, インコーポレイテッド | Cerebrospinal fluid purification system |
US9046192B2 (en) | 2007-01-31 | 2015-06-02 | The Charles Stark Draper Laboratory, Inc. | Membrane-based fluid control in microfluidic devices |
US7844345B2 (en) * | 2007-02-08 | 2010-11-30 | Neuropace, Inc. | Drug eluting lead systems |
US7813811B2 (en) * | 2007-02-08 | 2010-10-12 | Neuropace, Inc. | Refillable reservoir lead systems |
US8147480B2 (en) | 2007-09-28 | 2012-04-03 | Codman & Shurtleff, Inc. | Catheter for reduced reflux in targeted tissue delivery of a therapeutic agent |
US7766875B2 (en) * | 2007-09-28 | 2010-08-03 | Codman & Shurtleff, Inc. | Catheter for reduced reflux in targeted tissue delivery of a therapeutic agent |
WO2009055000A1 (en) | 2007-10-23 | 2009-04-30 | Optima Neuroscience, Inc. | System for seizure monitoring and detection |
US8868176B2 (en) | 2008-07-22 | 2014-10-21 | New York University | Microelectrode-equipped subdural therapeutic agent delivery strip |
KR101044661B1 (en) | 2008-12-26 | 2011-06-28 | 서울대학교산학협력단 | Drug delivery device with micropump for neural probe and metho of manufacturing the same |
EP3138603A1 (en) * | 2009-03-20 | 2017-03-08 | Incube Labs, Llc | Solid drug delivery apparatus, formulations and methods of use |
CA2699596A1 (en) | 2010-03-24 | 2011-09-24 | Hydro-Quebec | System and method of phase synchronization of signals produced by respective units of measure |
US9233237B2 (en) | 2010-08-26 | 2016-01-12 | New York University | Apparatus and method for periodic fluid-delivery/fluid-removal cycles in the cranial subarachnoid space to treat cerebral cortical disorders |
WO2012106501A1 (en) | 2011-02-02 | 2012-08-09 | The Charles Stark Draper Laboratory, Inc. | Drug delivery apparatus |
US8516568B2 (en) | 2011-06-17 | 2013-08-20 | Elliot D. Cohen | Neural network data filtering and monitoring systems and methods |
US20150038948A1 (en) * | 2013-07-31 | 2015-02-05 | G-Tech Electronic Research & Development, LLC | Apparatus and use of a neurochemisrty regulator device insertable in the cranium for the treatment of cerebral cortical disorders |
US11147540B2 (en) | 2015-07-01 | 2021-10-19 | Minnetronix, Inc. | Introducer sheath and puncture tool for the introduction and placement of a catheter in tissue |
ES2944452T3 (en) | 2015-12-04 | 2023-06-21 | Minnetronix Inc | Cerebrospinal fluid conditioning systems |
US20210213279A1 (en) * | 2016-09-16 | 2021-07-15 | Precision Neuroscience LLC | Conformal electrode arrays for electrophysiologic recording and neural stimulation within the cerebral ventricles and cerebral vasculature |
WO2018081002A1 (en) * | 2016-10-24 | 2018-05-03 | The Cleveland Clinic Foundation | Systems for creating one or more lesions in neurological tissue |
WO2019147203A2 (en) * | 2017-08-08 | 2019-08-01 | Ataturk Universitesi Bilimsel Arastirma Projeleri Birimi | Neurotransmitter monitoring and treatment device |
WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
WO2020056418A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
CN110180054A (en) * | 2019-07-04 | 2019-08-30 | 山西医科大学 | A kind of closed loop drug delivery systems |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4280494A (en) | 1979-06-26 | 1981-07-28 | Cosgrove Robert J Jun | System for automatic feedback-controlled administration of drugs |
DE3138320A1 (en) * | 1981-09-25 | 1983-04-14 | Siemens AG, 1000 Berlin und 8000 München | INFUSION DEVICE PROVIDED FOR IMPLANTATION IN A LIVING BODY |
EP0743839A4 (en) * | 1994-02-09 | 1999-02-10 | Univ Iowa Res Found | Human cerebral cortex neural prosthetic |
US5697975A (en) * | 1994-02-09 | 1997-12-16 | The University Of Iowa Research Foundation | Human cerebral cortex neural prosthetic for tinnitus |
US6094598A (en) | 1996-04-25 | 2000-07-25 | Medtronics, Inc. | Method of treating movement disorders by brain stimulation and drug infusion |
US5713923A (en) * | 1996-05-13 | 1998-02-03 | Medtronic, Inc. | Techniques for treating epilepsy by brain stimulation and drug infusion |
US6128537A (en) | 1997-05-01 | 2000-10-03 | Medtronic, Inc | Techniques for treating anxiety by brain stimulation and drug infusion |
US6186982B1 (en) * | 1998-05-05 | 2001-02-13 | Elan Corporation, Plc | Subcutaneous drug delivery device with improved filling system |
US6248080B1 (en) * | 1997-09-03 | 2001-06-19 | Medtronic, Inc. | Intracranial monitoring and therapy delivery control device, system and method |
US6016449A (en) | 1997-10-27 | 2000-01-18 | Neuropace, Inc. | System for treatment of neurological disorders |
US6315769B1 (en) * | 1999-09-13 | 2001-11-13 | Medtronic, Inc. | Apparatus and method for measuring the amount of fluid contained in an implantable medical device |
-
2000
- 2000-08-09 US US09/634,172 patent/US6497699B1/en not_active Expired - Fee Related
-
2001
- 2001-08-09 WO PCT/US2001/024870 patent/WO2002011703A1/en active IP Right Grant
- 2001-08-09 EP EP01959659A patent/EP1311245A4/en not_active Withdrawn
- 2001-08-09 AU AU8119001A patent/AU8119001A/en not_active Withdrawn
- 2001-08-09 JP JP2002517040A patent/JP2004505675A/en active Pending
- 2001-08-09 CA CA2418070A patent/CA2418070C/en not_active Expired - Fee Related
- 2001-08-09 HU HU0301698A patent/HUP0301698A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0301698A2 (en) | 2003-08-28 |
WO2002011703A1 (en) | 2002-02-14 |
EP1311245A1 (en) | 2003-05-21 |
US6497699B1 (en) | 2002-12-24 |
EP1311245A4 (en) | 2008-09-03 |
JP2004505675A (en) | 2004-02-26 |
WO2002011703A9 (en) | 2003-04-03 |
CA2418070A1 (en) | 2002-02-14 |
AU8119001A (en) | 2002-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2418070C (en) | Hybrid neuroprosthesis for the treatment of brain disorders | |
US11745014B2 (en) | Brain stimulation system including multiple stimulation modes | |
US7353065B2 (en) | Responsive therapy for psychiatric disorders | |
Rutten | Selective electrical interfaces with the nervous system | |
US7155279B2 (en) | Treatment of movement disorders with drug therapy | |
US8942809B2 (en) | Systems and methods for improving a cognitive function | |
US7610095B2 (en) | Diagnosis, treatment, and research of brain disorders | |
US7421297B2 (en) | Monopolar stimulation assembly including at least one remote electrode | |
US9352145B2 (en) | Methods and systems for treating a psychotic disorder | |
US8515541B1 (en) | Methods and systems for treating post-stroke disorders | |
US20070038264A1 (en) | Methods and systems for treating autism | |
US20070118197A1 (en) | Probe for Identifying Injection Site for Deep Brain Neural Prostheses | |
US20020013612A1 (en) | System and method for treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion | |
US20060178709A1 (en) | Methods and systems for treating a medical condition by promoting neural remodeling within the brain | |
US9095713B2 (en) | Methods and systems for treating autism by decreasing neural activity within the brain | |
US8577470B2 (en) | Systems and methods for improving memory in Alzheimer's patients | |
AU2001281190B2 (en) | Hybrid neuroprosthesis for the treatment of brain disorders | |
Lega et al. | Brain-machine interfaces: electrophysiological challenges and limitations | |
AU2001281190A1 (en) | Hybrid neuroprosthesis for the treatment of brain disorders | |
US20230062062A1 (en) | Detection of neural potential evoked in response to electrical stimulation | |
Di Florio et al. | Design of an experimental setup for delivering intracortical microstimulation in vivo via Spiking Neural Network | |
Kent | Characterization of evoked potentials during deep brain stimulation in the thalamus | |
Hetling | Prospects for building a therapeutic cortical stimulator | |
CN116917000A (en) | Methods and systems for deep brain stimulation of the basal ganglia of Meinate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed | ||
MKLA | Lapsed |
Effective date: 20110809 |